Evidence map›Paper›PMID 38435516›Full record

ArticleACS central science2024

Dissecting the Ability of Siglecs To Antagonize Fcγ Receptors.

Kelli A McCord, Chao Wang, Mirjam Anhalt, Wayne W Poon, Amanda L Gavin, Peng Wu, Matthew S Macauley

Open access · diamondAbstract read
In one paragraph

Article in ACS central science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
9.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Chemoradiotherapy facilitates siglec-10Cancer immunology, immunotherapy : CII · 2026
    Article
  5. Review
  6. Methods for Investigating Siglec-Ganglioside Interactions.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Induced proximity at the cell surface.Nature biotechnology · 2025
    Review
  13. Review
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Kelli A McCordDepartment of Chemistry, University of Alberta, 11227 Saskatchewan Drive, Edmonton, Alberta T6G 2G2, Canada.
Chao WangDepartment of Molecular Medicine, Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States.ORCID https://orcid.org/0000-0002-0878-9849
Mirjam AnhaltDepartment of Chemistry, University of Alberta, 11227 Saskatchewan Drive, Edmonton, Alberta T6G 2G2, Canada.
Wayne W PoonInstitute for Memory Impairments and Neurological Disorders, University of California, Irvine, California 92617, United States.
Amanda L GavinDepartment of Immunology and Microbiology, Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States.
Peng WuDepartment of Molecular Medicine, Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States.ORCID https://orcid.org/0000-0002-5204-0229
Matthew S MacauleyDepartment of Chemistry, University of Alberta, 11227 Saskatchewan Drive, Edmonton, Alberta T6G 2G2, Canada.ORCID https://orcid.org/0000-0003-4579-1048
Scripps Research Institute · USUniversity of Alberta · CAUniversity of California, Irvine · US

Funding

Exploring Siglec-glycan ligand interactions using chemoenzymatic approachesR01AI154138 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI WU, PENG · 2021 to 2025
$4.1M
Functions of novel phospholipase D proteins in nucleic acid sensingR01AI142945 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI NEMAZEE, DAVID · 2019 to 2023
$2.4M
Cell autonomous and non-cell autonomous phenotypes due to genetic risk for late onset Alzheimers diseaseRF1AG068992 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI POON, WAYNE W · 2021 to 2021
$2.2M
Cell autonomous and non-cell autonomous phenotypes due to genetic risk for late onset Alzheimers diseaseR01AG068992 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI POON, WAYNE W · 2024 to 2025
$1.4M
NIAID NIH HHS R01 AI142945NIAID NIH HHS R01 AI154138NIA NIH HHS R01 AG068992NIA NIH HHS RF1 AG068992
6 · The paper itself

Abstract

Fcγ receptors (FcγRs) play key roles in the effector function of IgG, but their inappropriate activation plays a role in several disease etiologies. Therefore, it is critical to better understand how FcγRs are regulated. Numerous studies suggest that sialic acid-binding immunoglobulin-type lectins (Siglecs), a family of immunomodulatory receptors, modulate FcγR activity; however, it is unclear of the circumstances in which Siglecs can antagonize FcγRs and which Siglecs have this ability. Using liposomes displaying selective ligands to coengage FcγRs with a specific Siglec, we explore the ability of Siglec-3, Siglec-5, Siglec-7, and Siglec-9 to antagonize signaling downstream of FcγRs. We demonstrate that Siglec-3 and Siglec-9 can fully inhibit FcγR activation in U937 cells when coengaged with FcγRs. Cells expressing Siglec mutants reveal differential roles for the immunomodulatory tyrosine-based inhibitory motif (ITIM) and immunomodulatory tyrosine-based switch motif (ITSM) in this inhibition. Imaging flow cytometry enabled visualization of SHP-1 recruitment to Siglec-3 in an ITIM-dependent manner, while SHP-2 recruitment is more ITSM-dependent. Conversely, both cytosolic motifs of Siglec-9 contribute to SHP-1/2 recruitment. Siglec-7 poorly antagonizes FcγR activation for two reasons: masking by cis ligands and differences in its ITIM and ITSM. A chimera of the Siglec-3 extracellular domains and Siglec-5 cytosolic tail strongly inhibits FcγR when coengaged, providing evidence that Siglec-5 is more like Siglec-3 and Siglec-9 in its ability to antagonize FcγRs. Additionally, Siglec-3 and Siglec-9 inhibited FcγRs when coengaged by cells displaying ligands for both the Siglec and FcγRs. These results suggest a role for Siglecs in mediating FcγR inhibition in the context of an immunological synapse, which has important relevance to the effectiveness of immunotherapies.

Identifiers

PMID38435516
PMCPMC10906256
OpenAlexW4390945491

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.